Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05732571
Other study ID # 22023
Secondary ID Post COVID-19 RE
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 10, 2023
Est. completion date July 30, 2024

Study information

Verified date June 2024
Source University of Nottingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A pilot Study To investigate the efficacy of a breathing intervention for improving persistent breathlessness due to dysregulated breathing following COVID-19 when compared to usual care.


Description:

Pilot RCT for upto 60 subjects across 2 arms Intervention A 12 session/six week, twice a week online group-based intervention based on breathing techniques including yoga practice directed by a specialist. Each group will aim for between 3- 6 participants. Each online session will be circa 40-50 minutes in length. This will include an Introduction and warm up; Breathing practice including yogic breathing and a final cool down and relaxation. Sessions will run at set times to ensure efficient use of resources but will try to accommodate different time points periods of the day when patients might be functioning best. Comparator A six week non-intervention (usual care) period will be recruited to, allowing a comparison to the intervention. Primary co-outcomes Change in - Breathlessness: Chronic Respiratory Disease Questionnaire-Dyspnoea domain (CRQ-D) - Functional measure: 5 repetition chair to stand (5RCTS) Secondary measures include other measures of breathlessness, function, adherence and completion (see full text for detail).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date July 30, 2024
Est. primary completion date July 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Either hospitalised or non-hospitalised with confirmed COVID-19 acute infection. - Received a comprehensive clinical respiratory assessment - Persisting (>12 weeks) self-reported breathlessness (on CRQ-D) following COVID-19 and confirmed dysregulated breathing (Nijmegen Questionnaire score NQ >23) - Age 18 - 80 years of age - Ability to give informed consent - Able to understand and speak English language Exclusion Criteria: - Severe mood disturbance that limits engagement with the intervention and study outcomes - No access to online delivery and/or IT illiterate - Significant diagnosed Myalgic Encephalitis/Fibromyalgia/Chronic Fatigue Syndrome prior to developing COVID-19 - Severe asthma or other chronic lung disease prior to COVID-19

Study Design


Intervention

Other:
Breathing techniques over 12 sessions / 6 weeks inc yoga
as above

Locations

Country Name City State
United Kingdom Nottingham University Hospitals Trust Nottingham Notts

Sponsors (1)

Lead Sponsor Collaborator
University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Breathlessness. Chronic Respiratory Disease Questionnaire - Dyspnoea Domain Range 1-7 with lower - worse 7 weeks
Primary Function 5 repetition chair to stand. Range 0-120 seconds with longer worse 7 weeks
Secondary Dyspnoea-12 Questionnaire SOB questionnaire. Range 0-36, Greater, worse 7 weeks
Secondary Nijmegen Questionnaire Measure of dysregulated breathing. 0-64. Greater worse 7 weeks
Secondary Borg Scale of Breathlessness Measure of breathlessness. Range 0-10. Greater worse 7 weeks
Secondary Four metre Gait speed field test of physical performance. Range 0-60seconds. Greater worse 7 weeks
Secondary Modified Minnesota Physical Activity Questionnaire. Range 0-100. Greater better. 7 weeks
Secondary Capnography - in some volunteers End tidal CO2 measure in breath - at rest. Range N/A 7 weeks
Secondary Chalder Fatigue Score Questionnaire. Range 0-33. Greater worse 7 weeks
Secondary EQ5D Quality of Life score Questionnaire. VAS 0-100. Greater is better. 7 weeks
Secondary Adherence Recorded from number of potential sessions. Range 0-12. Greater better. 7 weeks
Secondary Breath hold, Respiratory rate Observational measures at rest. Breath hold - 0-45. Greater better. RR. Range 0-30. Greater worse 7 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure